This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma

This study has been completed.
Information provided by (Responsible Party):
Taiho Pharmaceutical Co., Ltd. Identifier:
First received: October 30, 2008
Last updated: March 22, 2012
Last verified: March 2012
The purpose of this study is to evaluate the safety and efficacy of Orantinib, an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor, and fibroblast growth factor receptor, in patients with advanced hepatocellular carcinoma (HCC).

Condition Intervention Phase
Hepatocellular Carcinoma Drug: Orantinib (TSU-68) Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma

Further study details as provided by Taiho Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Step 1(Phase I) Safety [ Time Frame: During chemotherapy ]
  • Step 2(Phase II) Response rate(RR) [ Time Frame: Until progression ]

Secondary Outcome Measures:
  • Step 1(Phase I) Response rate(RR) [ Time Frame: Until progression ]
  • Step 2(Phase II) Safety [ Time Frame: During chemotherapy ]

Enrollment: 35
Study Start Date: September 2003
Study Completion Date: March 2012
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Orantinib (TSU-68)
200 or 400 mg bid day 1~day 28 cycle until progression or unacceptable toxicity develops

Detailed Description:
As HCC is a highly vascular tumor, a number of antiangiogenic agents have been tested for the treatment of HCC. Orantinib is an orally administered, small-molecule, multiple receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). Phase I studies that have been conducted in Japan for patients with solid tumors recommended a dosage of 400 mg bid. As a potent antiangiogenic agent, Orantinib is also expected to be effective against HCC. However, because most HCC patients have accompanying liver cirrhosis or hepatitis, its safety must be reevaluated in the presence of liver function impairment.

Ages Eligible for Study:   20 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 20-74
  • PS 0-2
  • Patients who did not respond to surgery, RFA, TAE, chemotherapy, or radiotherapy
  • Chid-Pugh A or B
  • At least one measurable lesion by RECIST criteria

Exclusion Criteria:

  • Large amount of pleural effusion or ascites
  • Esophageal varices
  • Simultaneously active double cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00784290

Chiba University Hospital
Inohana Chuo-ku Chiba, Chiba, Japan, 260-8670
Sponsors and Collaborators
Taiho Pharmaceutical Co., Ltd.
Study Chair: Masao Omata, M.D. Yamanashi Prefectural Central Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Taiho Pharmaceutical Co., Ltd. Identifier: NCT00784290     History of Changes
Other Study ID Numbers: Taiho132070
Study First Received: October 30, 2008
Last Updated: March 22, 2012

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on July 21, 2017